Tissue biopsy is the gold standard for the analysis of prognostic and predictive biomarkers. 1 However, in practice, tissue sampling is sometimes not feasible 2 and liquid biopsy with circulating tumour DNA (ctDNA) analysis by next-generation sequencing (NGS) can provide a viable alternative. Liquid biopsy based on ctDNA has become a reliable and convenient tool for the comprehensive genomic assessment of non-small-cell lung cancer (NSCLC) patients for identifying actionable mutations as well as co-mutations and acquired resistance alterations. [3] [4] [5] In recent clinical trials of immunotherapy for advanced NSCLC patients, TMB based on plasma ctDNA also exhibited good performance as a prognostic biomarker. 6
Osimertinib is an irreversible third-generation EGFR-TKI targeting the secondary resistant EGFR T790M mutant with outstanding clinical efficacy. 7, 8 Unfortunately, acquired resistance still occurs after a median of 10 months 4 with various resistance mechanisms. [9] [10] [11] [12] [13] Moreover, emerging data indicated the co-occurrence of TP53 mutations is associated with shortened progression-free survival. [14] [15] [16] Identifying other acquired mutations during treatment could allow better prognostication and therapeutic strategies.
In this study, we enrolled thirty-six EGFR-mutant advanced lung adenocarcinoma patients, who were confirmed T790M-positive based on tumour tissue genotyping assay, and investigated the clinical implications of serial analysis using a 1021 gene capture panel of ctDNA during osimertinib treatment. Our results implied a broad potential of ctDNA as an adjuvant tool in practical clinical management.
| MATERIAL S AND ME THODS

| Study population
A total of 36 metastatic lung adenocarcinoma patients with acquired EGFR T790M mutations were enrolled from National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. The study was reviewed and approved by Ethics Committee of this institution. All patients provided written contents according to ethical regulations. For each patient, a volume of 10 mL blood was collected before osimertinib treatment, at individual response assessment time-point and after disease progression. Response assessments were performed every 3 months during treatment. Progression-free survival (PFS) was measured from the beginning of osimertinib treatment to progression confirmed by computer tomography (CT) scan according to RECIST 1.1, 17 or treatment cessation, or death.
| Targeted NGS and data processing
cfDNA extraction and library construction were performed according to previous publication. 18 
| Pyclone and TMB analysis
PyClone was used to analyse the clonal population structure of ctDNA collected serially from each patient. 20 The copy number information of each single nucleotide variation (SNV) was used as input. Variants located in the cluster with greatest mean cancer cell fraction (CCF) were defined as clonal and the rest were subclonal.
TMB of blood (bTMB) was analysed using SNVs (non-synonymous only) and indels at allele frequencies of ≥0.5%. The cut-off value for bTMB-H and bTMB-L is defined as 9 mutations/Mb, approximately the median value in our assay experience. (42%) had received only first-generation EGFR-TKI; 2 (5%) had only chemotherapy; and 19 (53%) had been previously exposed to both first-generation EGFR-TKI and chemotherapy. 
| Statistical analysis
| Pre-treatment ctDNA features correlate with progression-free survival
The somatic mutation profiles of the pre-treatment plasma samples are shown in Figure 1 (n = 34, 2 patients who were ctDNA-negative were not presented in the figure) . Twenty-nine of the 36 patients (72.2%) had detectable T790M in plasma. A high concordance was also observed for the common EGFR-sensitizing mutations between pre-treatment plasma and tissue samples: 30 of the 36 patients were positive, with 21 (58%) 19del, 9 (25%) L858R and 1 (2.7%) S768I.
The ctDNA sensitivities of these three genotypes were 88% (21/24), 82% (9/11) and 100% (1/1), respectively.
To better characterize the co-occurring genetic prognostic features, the patients were divided into two subgroups according to a PFS cut-off value of 10 months (Figure 1 We then explored the PFS in patient subgroups divided by EGFR L858R/19del genotype, T790M, TP53 status and additional drivers. The patients with 19del, T790M-positive, T790M-subclonal and the subgroup negative for additional driver gene mutations a shorter median PFS than the other subgroups ( Figure S2 ), but the differences were not statistically significant (all P > .05).
However, patients with suppressor gene mutations or TP53 mutations alone had significantly worse outcomes than those without these mutations (P = .04; Figure 2A Herein we analysed the correlation between bTMB and the prognosis. Of interest, the bTMB-H subgroup showed a significantly shorter PFS (244 days) than the bTMB-L subgroup (P = .016; Figure 2C ). The patients in shorter PFS group had a median bTMB value of 7.9 mutations/Mb, significantly higher than those in longer PFS group (bTMB = 3.2; Figure 2F ). These results suggest that TP53 and the bTMB in pre-treatment plasma samples were two potentially clinically useful prognostic features in osimertinib treatment patients.
| Therapeutic response monitoring using serial ctDNA
Twelve patients experienced disease progression, 3 of whom had PR and 9 had stable disease (SD) at the first response assessment.
Eleven of these 12 patients had pre-treatment ctDNA detectable at baseline. In order to analyse the correlation between the change of ctDNA level and the change of tumour size in the patients, we defined the difference between the frequency of the ctDNA gene ctDNA failed to reflect disease progression in a non-target lesion in one patient, which may due to the small tumour size ( Figure S3 ) and subsequent low ctDNA infiltration rate.
| Resistance mechanism in twelve progressed patients indicated by paired ctDNA
Nine of the 12 progressed patients (75%) harboured EGFR T790M mutation in their pre-treatment ctDNA. Only one patient maintained the T790M in ctDNA at the time of PD, with the emergence of a concomitant C797S mutation. The loss of T790M at resistance may therefore contribute to drug resistance. In addition to T790M loss, other possible resistance mechanisms were identified in 7 patients. The dynamic change of different mutant clusters of the six patients who had more than two ctDNA time-points during treatment is shown in Figure 4 . Among them, four were found to have potential resistant mutations in pre-treatment samples.
Two novel EGFR mutations, K754I and T751I, were detected along with 19del in pre-treatment ctDNA (n = 1). Upon PD, T790M was completely lost while K754I and T751I clones were dramatically increased. PIK3CA E542K was also found at PD (n = 1), although All acquired mutations at PD are presented in Figure 5 . The three patients who had PFS < 3 months had more acquired mutations than others ( Figure S4 ).
All EGFR family mutations found in the 12 progressed patients are annotated in schematic models in Figure 6 . Six of these EGFR muta- 
| D ISCUSS I ON
Compared to tissue biopsy, liquid biopsy, especially ctDNA sequencing, allows comprehensive and longitudinal monitoring of tumour F I G U R E 5 Acquired mutations during treatment in eleven patients who have both positive pre-treatment and positive after treatment ctDNA results. P036 is not shown due to the lack of after treatment ctDNA data. Alteration types are represented by the same colours as listed in Figure 1 . Patients suffered super progression, defined by a <3 mo PFS, are indicated in dark purple, otherwise in pink F I G U R E 6 Positions of the EGFR (A) and ERBB2 (B) mutations identified in PD patients. The domain organizations of EGFR are shown with site mutations annotated by sticks. The crystal structure of wild-type EGFR extracellular domains and kinase domain is presented. Four extracellular domains are shown in different colours. A schematic model for the two extracellular mutations is also presented genomics non-invasively. While the correlation of ctDNA and efficacy of EGFR-TKI has been extensively investigated, 21 this work presents one of the most comprehensive ctDNA genomic analyses of tumour evolution during osimertinib treatment, which is a thirdgeneration EGFR-TKI. The present study demonstrated that ctDNA is an important approach to predict prognosis and monitor response.
Concurrent mutations, especially TP53, KRAS and PIK3CA, are common in EGFR-mutated NSCLC. Coexisting TP53 mutations were generally associated with shorter survival in first-generation EGFR-TKI therapy. 14, 22 In our study, TP53 mutations and tumour suppressor genes strongly correlated with a worse outcome during osimertinib treatment. It is worth noting that one particular patient harbouring multiple other suppressor gene mutations without TP53 mutation had a PFS ≥ 10 months.
T790M is another ctDNA feature extensively discussed as a prognostic marker in osimertinib treatment. The sensitivity of pretreatment ctDNA T790M is 73% in our cohort with documented tissue T790M which is similar to previous studies. 23 Tissue-based TMB (tTMB) is an emerging biomarker of response to checkpoint inhibitor treatment. 26, 27 Recent studies have reported the utility of bTMB in predicting the clinical outcomes. 6 In EGFR-TKI treatment, TMB is rarely discussed since tumours with EGFR sensitive mutation usually have a low TMB. Consistent with this general concept, only 6 patients were TMB-H in our cohort, using a cut-off value selected from our own NSCLC database using this platform and there was a significant difference on PFS between bTMB-H and bTMB-L subgroups. With the intriguing observation of unexpectedly good outcomes with the atezolizumab/bevacizumab combination in EGFR-mutant patients in IMPower 150, TMB could emerge as an important marker in this subgroup.
Besides monitoring therapeutic response and clonality evolution, [28] [29] [30] [31] [32] ctDNA has been indicated to detect the development of tumour heterogeneity, providing earlier detection of disease progression or recurrence. In our study, 5 patients with progression in non-target lesions showed obvious increases of ctDNA. Four of these five patients had brain or liver metastases, suggesting that a clinically significant signal of emerging lesions could be detected by ctDNA. ctDNA can detect small insidious lesions which cannot be detected with routine imaging, possibly because it can draw a whole picture of the tumour burden. However, for patients with small lesion or low level of ctDNA, the ability of ctDNA to track progression is precluded to some extent. We did not see earlier ctDNA detection of progression before CT-based assessment of disease progression as previously reported, which may due to a less frequent ctDNA sampling time-points in this study but suggests that early detection of progression by ctDNA may not be clinically significant.
In spite of several mechanisms identified correlated with resistance, the complex resistance mechanism is not obvious. ctDNA pre-treatment and at PD provide hints for better understanding the resistant mechanisms such as EGFR C797S, G724S, G719R, KRAS G12D, PIK3CA E542K, EGFR amplification and ERBB2 amplification. Other potential EGFR-dependent resistance mechanisms were identified, including EGFR T751I and K754E in the kinase domain, and D321N and M137R in extracellular domain. It is difficult to perform a docking simulation for the binding of EGFR T751I/K754E and osimertinib because of the unavailability of local structure around A750. 33 Although rarely reported, some EGFR extracellular domain mutations have been correlated with resistance to EGFR-TKI. 34 Further functional experiments would help to investigate binding mode changes of the TK domain mutants and EGFR activity changes as a consequence of the two extracellular mutants. Despite extensive structural homology of the extracellular putative ligand binding region, ERBB2 has no identified direct ligand. Instead, it acts as the preferred dimerization partner for all other ERBB family receptors. 35 A novel mutation ERBB2
S603C was discovered located in the extracellular domain. We speculated that the new cysteine in subdomain IV of extracellular domain may lead into improper dimerization between ERBB family members and cause alternative pathway activation.
| CON CLUS IONS
Our study explored the potential applications of serial ctDNA analysis in the management of advanced lung adenocarcinoma patients.
ctDNA could help with clinical practice during osimertinib treatment, regarding monitoring tumour response, detecting development of heterogeneity, identifying potential resistance mechanisms, predicting treatment efficacy and patient outcome.
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